Fundz

Hyku Biosciences reported raising $8.61 Million in an initial SEC Form D filing, from an offering of $8.61 Million

PRIVATEAug 13, 2026

Amount Raised

$8.61 Million

$8.61 Million sold, per SEC Form D (first sale Jul 30, 2026)

Round Type

Venture

LexingtonBiotechnologyHealth CareTherapeutics

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Hyku Biosciences that raised within 45 days of this round, from Fundz verified event records.

  • Cerenome, Inc. raised $3M (Post-IPO Equity) on September 10, 2026.
  • CONNECTA Therapeutics raised $3.6M (Seed) on September 10, 2026.
  • Cerenome, Inc. raised $20M (Debt Financing) on September 10, 2026.
  • Navion Neurosciences raised $11M (Seed) on September 9, 2026.
  • Encoded Therapeutics raised $275M (Series F) on September 9, 2026.
  • Newron Pharmaceuticals S.p.A. & EA Pharma Ltd raised $6.4M on September 8, 2026.

Who to call at Hyku Biosciences, and when

A new round usually means Hyku Biosciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Hyku Biosciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Hyku Biosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Hyku Biosciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Hyku Biosciences

Location

Lexington, Massachusetts, United States

About

Hyku is a biotechnology company based in the greater Boston area, utilizing its proprietary discovery platform to inhibit disease targets that are challenging to address with conventional approaches. Hyku’s drug discovery engine is based on its proprietary platform technologies, which identify histidine, tyrosine and lysine-based binding pockets and enable rational drug design for the development of covalent or non-covalent medicines. The platform pioneered by Hyku has the potential to fundamentally expand the scope of small molecule drug discovery, greatly increase the potential to modulate many target classes, and bring significant therapeutic benefits to patients via first-in-class and best-in-class medicines.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Hyku Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Predictive Intelligence
Strategic

ML-powered predictions for Hyku Biosciences's next move

See what Strategic adds

Hyku Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.